−0.001 BRL
−697.65 M BRL
2.32 B BRL
About Intra-Cellular Therapies Inc.
Sector
CEO
Sharon L. Mates
Headquarters
Bedminster
Website
Founded
2002
ISIN
BRI2TCBDR009
FIGI
BBG01HH21FM9
Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm’s lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates in 2002 and is headquartered in Bedminster, NJ.
Displays a symbol's price movements over previous years to identify recurring trends.